publication date: Jan. 3, 2020
NCCN pediatric cancer guidelines focus on improving long-term outcomes worldwide
The National Comprehensive Cancer Network published new guidelines for treating children, adolescents and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma.
NCCN published the first pediatric NCCN Clinical Practice Guidelines in Oncology in 2019, which addressed acute lymphoblastic leukemia.
Historically, most children with cancer in the United States have been included on active clinical trials, with clear protocols in place to standardize treatment and maximize response, while addressing potential toxicities. However, improved cure rates and decreased research funding have resulted in more patients being treated outside of clinical trials, where treatment guidelines are lacking.
The new guidelines are intended to make sure management is provided in the best possible manner to improve both short- and long-term outcomes. Globally, (especially in resource-constrained settings) many patients do not have access to oncologists who specialize in pediatric cancers, making guidelines highly relevant for these situations.
NCCN plans to adapt these guidelines into NCCN Harmonized Guidelines for Sub- Saharan Africa, which take into account specific regional concerns and potential resource limitations.
The organization will also continue expanding into pediatric recommendations with upcoming NCCN Guidelines for Wilms Tumor and Pediatric Hodgkin Lymphoma.
The guidelines are posted here.
SWOG study focuses on impact of vitamin and antioxidant supplement use in cancer patients
In a study of more than 1,600 patients with breast cancer undergoing chemotherapy, researchers found several associations between supplement use.
Of the patients with breast cancer who were enrolled in a randomized phase III trial led by SWOG … Continue reading NCCN pediatric cancer guidelines focus on improving long-term outcomes worldwide
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.